Skip to main content
. 2023 Mar 14;28(7):e508–e519. doi: 10.1093/oncolo/oyad040

Figure 2.

Figure 2.

PDL1 scoring with DAKO PD-L1 22C3 and Ventana PD-L1 SP142 in the total cohort (a) and NF2-mutated cohort (b). TPS, tumor proportion score; CPS, combined positive score; IC, immune cells.